ImaginAb and BZL Biologics have signed a collaborative licensing agreement for imaging rights to huJ591/Prostate-Specific Membrane Antigen antibody technology for diagnostic imaging with PET and SPECT.

The technology, in conjunction with ImaginAb’s antibody fragment solution, could benefit prostate cancer patients by improving diagnostic accuracy and disease monitoring, according to the companies.

PSMA is a target for prostate cancer and is expected to translate into the clinic in 2010.